Analysts Set Denali Therapeutics Inc. (NASDAQ:DNLI) Price Target at $40.22

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have been assigned an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $40.22.

Several research firms have weighed in on DNLI. Wedbush reduced their target price on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, May 8th. Stifel Nicolaus reduced their target price on Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating on the stock in a report on Wednesday, May 8th. The Goldman Sachs Group reduced their target price on Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating on the stock in a report on Thursday, February 29th. UBS Group reduced their target price on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, April 9th. Finally, HC Wainwright reiterated a “buy” rating and set a $95.00 target price on shares of Denali Therapeutics in a report on Wednesday, May 8th.

Denali Therapeutics Stock Down 1.7 %

Shares of Denali Therapeutics stock opened at $22.00 on Monday. Denali Therapeutics has a 12 month low of $14.56 and a 12 month high of $30.79. The business has a fifty day simple moving average of $19.18 and a 200 day simple moving average of $19.24. The stock has a market cap of $3.14 billion, a PE ratio of -22.92 and a beta of 1.37.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.01. Denali Therapeutics had a negative return on equity of 11.46% and a negative net margin of 36.51%. During the same quarter in the previous year, the firm earned ($0.80) earnings per share. Analysts expect that Denali Therapeutics will post -2.78 EPS for the current fiscal year.

Insider Activity at Denali Therapeutics

In related news, Director Jennifer E. Cook sold 1,458 shares of Denali Therapeutics stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $21.73, for a total value of $31,682.34. Following the sale, the director now owns 20,038 shares of the company’s stock, valued at $435,425.74. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Denali Therapeutics news, Director Jennifer E. Cook sold 1,458 shares of the business’s stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $21.73, for a total transaction of $31,682.34. Following the transaction, the director now owns 20,038 shares of the company’s stock, valued at $435,425.74. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Vicki L. Sato sold 1,666 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $18.29, for a total value of $30,471.14. Following the transaction, the director now directly owns 118,043 shares in the company, valued at approximately $2,159,006.47. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 95,624 shares of company stock valued at $1,958,403. 7.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Denali Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. CWM LLC grew its position in shares of Denali Therapeutics by 216.7% in the fourth quarter. CWM LLC now owns 2,011 shares of the company’s stock valued at $43,000 after purchasing an additional 1,376 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Denali Therapeutics by 48.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock valued at $53,000 after buying an additional 807 shares during the period. Fisher Asset Management LLC bought a new stake in shares of Denali Therapeutics in the fourth quarter valued at approximately $59,000. Assetmark Inc. boosted its stake in shares of Denali Therapeutics by 65.3% in the fourth quarter. Assetmark Inc. now owns 3,550 shares of the company’s stock valued at $76,000 after buying an additional 1,402 shares during the period. Finally, Headlands Technologies LLC bought a new stake in shares of Denali Therapeutics in the first quarter valued at approximately $88,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.